bluebird bio, Inc. secures up to $175 million debt financing with Hercules Capital for commercial launches of FDA approved gene therapies.

Mar 18, 2024•over 1 year ago

Amount Raised

$175 Million

SomervilleHealth CareBiotechnology

Investors

Hercules Capital, Inc.

Description

bluebird bio, Inc. has entered into a $175 million five-year term loan facility with Hercules Capital, Inc. to strengthen its balance sheet for the commercial launches of its three FDA approved gene therapies - LYFGENIA for sickle cell disease, ZYNTEGLO for beta-thalassemia, and SKYSONA for cerebral adrenoleukodystrophy.

Company Information

Company

bluebird bio

Location

455 Grand Union Boulevard

Somerville, Pennsylvania, United States

About

bluebird bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. With more than a decade of scientific leadership in gene therapy and three FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, the company is committed to ensuring access, reliability, and patient-centered care.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends